Multiple onychocryptosis following treatment of onychomycosis with oral terbinafine

Cutis

Volumn 66, Issue 3, 2000, Pages 211-212

  Weaver, Terry D ^a,b   Jespersen, David L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b DES MOINES UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; NAPHTHALENE DERIVATIVE; TERBINAFINE;

ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; HUMAN; INGROWN NAIL; MALE; MIDDLE AGED; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; SKIN DISEASE;

ADMINISTRATION, ORAL; ANTIFUNGAL AGENTS; FOOT DERMATOSES; HUMANS; MALE; MIDDLE AGED; NAILS, INGROWN; NAPHTHALENES; ONYCHOMYCOSIS;

EID: 0034277150     PISSN: 00114162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Arenas R, Dominguez-Cherit J, Fernandez L. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermotol. 1995;34:138-143.
2. Joseph W. Oral treatment options for onychomycosis. JAPMA. 1997;87:520-531.
3. Katz H. Systemic antifungal agents uses to treat onychomycosis. J Am Acad Dermatol 1998;38:S48-S52.
4. DeBacker M, et al. Twelve weeks of continuous oral therapy for toenail onychomycosis caused by dermatophytes: a double-blind comparative trial of terbinafine 250 mg/day versus itraconazole 200 mg/day. J Am Acad Dermatol. 1998;38:S57-S63.
5. Elewski B. Diagnostic techniques for confirming onychomycosis. J Am Acad Dermatol. 1996;35;S6-S9.
6. Leyden J. Pharmacokinetics and pharmacology of terbinafine and itraconazole. J Am Acad Dermatol. 1998;38:S42-S46.